Simtra BioPharma Solutions, a injectable contract development and manufacturing organisation (CDMO), has announced a $250+ million expansion of its sterile fill/finish manufacturing campus in Bloomington, Indiana. A new, state-of-the-art 150,000 square foot building will be constructed to house two high-speed
Telix Pharmaceuticals, an Australian company, has announced its agreement to acquire IsoTherapeutics Group, LLC, a specialty radiopharmaceutical development and bioconjugation firm based in Angleton, Texas. This strategic move is set to bolster Telix’s in-house drug development capabilities and expand its US
In order to expand its capabilities, CoreRx, Inc. has announced a definitive agreement to acquire Societal CDMO, Inc. (NASDAQ: SCTL), a contract development and manufacturing organisation (CDMO) known for tackling complex formulation and manufacturing challenges. The transaction is expected to close early in
Pluri Inc., a biotechnology firm based in Haifa, Israel, recently announced the launch of two new business verticals. These are PluriAgtech and PluriCDMO, aimed at leveraging its cell-based technology in agriculture and providing contract development and manufacturing services, respectively. The company’s
Bajaj Healthcare has announced a definitive CDMO agreement with UK/EU based customers for the supply of 15 Active Pharmaceutical Ingredients (APIs). Under this agreement, Bajaj Healthcare will undertake the development and supply of these molecules. These APIs encompass a diverse range
Experic, a CDMO and clinical trial supply services company, has announced its expansion into Europe with a new facility in Dublin, Ireland. This strategic move is set to bolster the company’s global footprint and increase the efficiency of its worldwide
BioCina Pty Ltd., a end-to-end biologics Contract Development and Manufacturing Organisation (CDMO), and NovaCina Pty Ltd., a fill-and-finish CDMO, announced a strategic partnership to provide integrated drug substance and drug product solutions for biologics developers. This alliance enables BioCina to offer the highest
Microsize have announced the signing of a long-term supply agreement with Cerus Corporation to provide high-throughput particle sizing services for the functional powders used in the INTERCEPT® Blood System for Plasma. This pathogen inactivation technology is used by blood centres around
PharmaScience, the Canadian-owned pharmaceutical company, has announced a significant expansion of its Contract Development and Manufacturing Organisation (CDMO) services. This expansion follows the company’s recent $120 million sterile injectable manufacturing facility expansion at its Canadian site. The company has created a
BioHarvest Sciences, a biotechnology company focused in Botanical Synthesis process technology, has announced the official launch of its new Contract Development and Manufacturing Organisation (CDMO) business unit. The company has also announced that this new unit has recently signed two
Help us find the most innovative and trusted suppliers in Pharma and Biotech.
